Christian Dittrich

TL;DR: In heavily pretreated patients with locally advanced or metastatic breast cancer, 75 and 250 mg temsirolimus showed antitumor activity and 75 mg Temsiro Limus showed a generally tolerable safety profile.

TL;DR: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.

TL;DR: EpCAM independent enrichment technologies seem to be superior to detect the entire CTC population, and evaluation of CTCs as prognostic marker should compromise EpCAM (+) and (−) subpopulations.

TL;DR: Seven patients with various types of solid tumours refractory to standard therapy were treated with escalating doses of KP1019 twice weekly for 3 weeks, and the pharmacokinetic disposition was characterised by a small volume of distribution, low clearance and long half-life.

TL;DR: BJJ398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease, highlighting putative mechanisms of resistance to the agent, which may be useful in following disease status.